-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $357

Benzinga·10/30/2026 16:26:43
Listen to the news
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $345 to $357.